Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease

By sjmartinez • October 21, 2022

Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2022 Oct 20:gfac283. doi: 10.1093/ndt/gfac283. Epub ahead of print. PMID: 36264305.

Tags: cardiovascular disease, Chronic kidney disease, diabetes mellitus, glucagon-like peptide-1 receptor agonist, Nephrology, nonsteroidal mineralocorticoid receptor antagonist, Publications, sodium-glucose cotransporter-2 inhibitor

A case of karyomegalic interstitial nephritis without FAN1 mutations in the setting of brentuximab, ifosfamide, and carboplatin exposure

Leong M, Dai T, Tong L, Nast CC. A case of karyomegalic interstitial nephritis without FAN1 mutations in the setting of brentuximab, ifosfamide, and carboplatin[...]

CJASN: A Prelude to the Future

Rhee CM; CJASN Editorial Team. CJASN: A Prelude to the Future. Clin J Am Soc Nephrol. 2024 Nov 7. doi: 10.2215/CJN.0000000613. Epub ahead of print.[...]

Establishing a peritoneal dialysis technique survival core outcome measure: A standardised outcomes in nephrology-peritoneal dialysis consensus workshop report

Elphick EH, Manera KE, Viecelli AK, Craig JC, Cho Y, Ju A, Shen JI, Wilkie M, Anumudu S, Boudville N, Chow JS, Davies SJ, Gooden[...]